APA (7th ed.) Citation

O, J., DM, B., GL, I., CC, W., E, F., S, C., . . . AC, R. (2026). SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progression. Signal transduction and targeted therapy, 11(1), . https://doi.org/10.1038/s41392-026-02709-1

Chicago Style (17th ed.) Citation

O, Jung, Beauvais DM, Ibaan GL, Wooldrik CC, Flietner E, Choi S, Zhang J, and Rapraeger AC. "SSTNIV, a Syndecan-1-targeting Peptide Chimera, Reverses Immune Suppression and Inhibits Myeloma Progression." Signal Transduction and Targeted Therapy 11, no. 1 (2026). https://doi.org/10.1038/s41392-026-02709-1.

MLA (9th ed.) Citation

O, Jung, et al. "SSTNIV, a Syndecan-1-targeting Peptide Chimera, Reverses Immune Suppression and Inhibits Myeloma Progression." Signal Transduction and Targeted Therapy, vol. 11, no. 1, 2026, https://doi.org/10.1038/s41392-026-02709-1.